RESEARCH ARTICLE

Role of the MAPKs/TGF-β1/TRAF6 signaling pathway in postoperative atrial fibrillation

Daoliang Zhang1, Xiaoqing Chen2, Qian Wang3, Shaohui Wu1, Yue Zheng4, Xu Liu1*

1 Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China, 2 Department of Cardiology, Shanghai First People’s Hospital, Shanghai, People’s Republic of China, 3 Department of Cardiology, Shanghai Xinhua Hospital, Shanghai, People’s Republic of China, 4 Department of Cardiac Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China

* xkzhangdaoliang@126.com

Abstract

Objectives
To explore the relationship between the MAPKs/TGF-β1/TRAF6 signaling pathway and atrial fibrosis in patients with rheumatic heart disease (RHD) and its role in atrial fibrillation (AF) after cardiac surgery on the basis of our previous animal study of the MAPKs/TGF-β1/TRAF6 signaling pathway in atrial fibrosis.

Methods
A total of 57 patients with RHD without a history of AF consented to left atrial biopsy. Histopathology quantified the percentage of fibrosis, and real-time PCR and western blot assessed the mRNA and protein expression of TGF-β1, TRAF6, and connective tissue growth factor (CTGF), respectively. Western blot was also used to measure the protein expression of phosphorylated MAPKs and TGF-β-activated kinase 1 (TAK1). Serum angiotensin II (Ang II) levels were assayed using enzyme-linked immunosorbent assay (ELISA).

Results
Eighteen patients developed AF, whereas 39 remained in sinus rhythm (SR). The severity of atrial fibrosis was significantly higher in patients who developed AF versus those who remained in SR; the mRNA and protein expression of TGF-β1, TRAF6, and CTGF were significantly higher in patients with AF. The protein expression of phosphorylated MAPKs and TAK1 was significantly increased in patients who developed AF compared with the patients who remained in SR. Serum Ang II levels were significantly higher in patients who developed AF versus those who remained in SR.

Conclusion
The MAPKs/TGF-β1/TRAF6 signaling pathway is involved in atrial fibrosis in patients with RHD, which results in the occurrence of AF after cardiac surgery.
Introduction

Atrial fibrillation (AF) is the most common clinical arrhythmia and results in abnormal hemodynamics and thrombotic events that significantly increase morbidity and mortality [1–3]. Atrial fibrillation (AF) occurs in 30% of patients following cardiac surgery and contributes significantly to postoperative morbidity, mortality, and costs [4,5]. One study demonstrated that post-surgical AF was maintained by left atrial (LA) sources and was associated with pre-operative fibrosis [4]. However, the exact mechanism and signal transduction pathway underlying the occurrence and development of atrial fibrosis are unknown [6].

Our previous study demonstrated that the MAPKs/TGF-β1/TRAF6 signaling pathway was involved in mouse atrial fibroblast proliferation induced by AngII and participated in atrial remodeling [7]. The effect of TRAF6 on atrial structural remodeling is not completely clear, nor is the underlying mechanism of this effect, especially in the study of human atrial specimens. We aim to further elucidate the expression of TRAF6 and related signaling pathways in patients with rheumatic heart disease (RHD) and to explore the relationship between the signaling pathways and atrial fibrosis and the role they play in AF after cardiac surgery, based on analysis of recent studies of atrial structural remodeling.

Materials and methods

Patient recruitment

After approval from the ethics committee of Shanghai Chest Hospital, as well as the provision of written informed consent by each patient, from December 2013 to December 2014, a total of 57 patients with rheumatic heart disease following cardiac surgery in Shanghai Chest Hospital were enrolled in this study. All patients were given pre-operative cardiac Doppler ultrasound and coronary angiography, and were monitored by continuous ECG telemetry throughout their hospitalization for the presence of AF. In this study, medical records were reviewed to identify the exclusion criteria: history of AF, hyperthyroidism, sick sinus syndrome, pulmonary fibrosis, chronic pulmonary heart disease, cardiomyopathy, kidney disease, liver cirrhosis and patients undergoing a second heart surgery. Cardiac rhythms were defined by a blinded investigator. In addition, pharmacotherapy was discontinued in all patients 12 hours before surgery. All patients were treated following the Declaration of Helsinki of the World Medical Association.

Sample collection

Left atrial appendage tissue, which was collected before the initiation of extracorporeal circulation, was sectioned into several blocks. One block was fixed with 10% formalin solution for pathological examination, and the other blocks were stored in liquid nitrogen for real-time PCR and Western Blot analysis.

Histopathology

Specimens, as previously described, were pathologically examined using HE staining and Masson staining. After Masson staining, 4 sections were randomly selected from each patient for quantification of atrial fibrosis. These sections were observed under a Nikon eclipse 50i microscope, and 5 fields were randomly selected from each section. Myocytes were stained red, and collagen fibers were stained blue. Collagen fibers in the endocardium were determined under 400X magnification. Representative photographs were captured with NIS-Elements F camera system, and the proportion of collagen fibers was quantified with Image-Pro Plus 6.0 analysis.
The percentage of fibrotic area was calculated as follows: percentage of fibrotic area = fibrotic area / total area × 100.

Quantitative real-time PCR
Total RNA was extracted from tissue specimens with TRIzol (Invitrogen, USA) and was used to synthesize single-stranded complementary DNA with a high-capacity complementary DNA reverse transcription kit (Toyobo, JAPAN). Quantitative real-time RT-PCR involved the use of gene-specific primers (see Table 1 for details) and a SYBR kit (Takara, JAPAN). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. Results were expressed as fold difference for each gene against GAPDH by using the $2^{\Delta\Delta C\text{t}}$ method.

Serum Ang II level assay
Serum samples were taken 1 day before the surgery. Serum Ang II levels were measured using enzyme-linked immunosorbent assay kits (Enzo Biochem, USA).

Western blot assay
Left atrial appendage samples were rinsed in cold PBS, and then placed in a 1.5 ml round-bottom tube. Ice-cold RIPA buffer (Beyotime technology), PMSF (0.5ul/ml) and inhibitor of phosphatase was added at 4˚C. Total protein was extracted with Protein Extraction Kit (Thermo Scientific, USA) and protein concentration was measured using the BCA Protein Assay Kit (Thermo Scientific, USA), respectively. Protein samples were separated on 12% SDS-PAGE gels and transferred onto nitrocellulose membranes. After blocking with 5% BSA in tris-buffered saline with tween, the membranes were incubated overnight at 4˚C with primary antibodies against TGF-β1, CTGF, TRAF6 (Santa Cruz, USA), extracellular signal-regulated kinase1/2 (ERK1/2), phospho-ERK1/2, P38 MAPK, phospho-P38 MAPK, phospho-c-Jun NH(2)-terminal kinase (JNK), TAK1, phospho-TAK1, GAPDH (Cell Signaling Technology, USA), and JNK (Bioworld, USA). After washing, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody for 2 h at room temperature. Western blots were performed using SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific, USA) and quantified by scanning densitometry. The ratio of interested protein was normalized to GAPDH and was densitometrically analyzed by Quantity One software (USA).

Statistical analysis
Student’s t test was used to compare continuous variables between two groups, and the data for continuous variables were expressed as the mean ± SEM (standard error of the mean). A
Chi-square test was adopted to compare categorical variables between two groups. All statistical analyses were performed using SPSS 19.0. Statistical significance was assumed when \( p < 0.05 \).

**Results**

**Patient variables**

Of the 57 patients enrolled, 39 patients remained in SR, and 18 developed new onset postoperative AF. Table 2 presents the clinical characteristics of the enrolled patients.

**Histopathological staining and quantitative analysis of fibrotic area**

The results of the left atrial appendage HE staining and Masson staining are illustrated in Fig 1. Compared with the patients who remained in sinus rhythm (Fig 1A), HE staining showed that the atrial muscle cells of atrial appendage tissue in patients with postoperative AF were disordered and hypertrophic, (Fig 1B). Masson staining revealed obvious fibrosis for all patients in the two groups with rheumatic heart disease, but the percentage of fibrosis in the postoperative AF group was more significant (Fig 1C and 1D). The fibrosis grade of the postoperative AF group was significantly higher than that of the sinus rhythm group (\( p < 0.01 \); Fig 1E), which suggested that there was internal connection between preoperative atrial fibrosis and postoperative AF.

**Table 2. Patient variables.** 

|                  | AF After Surgery (n = 18) | SR (n = 39) | p-Value |
|------------------|--------------------------|------------|---------|
| Sex (male/female)| 8/10                     | 21/18      | 0.51    |
| Age (years)      | 56.4±2.6                 | 56.0±1.4   | 0.86    |
| Hypertension     | 5                        | 8          | 0.54    |
| Diabetes mellitus| 4                        | 7          | 0.7     |
| LVEF (%)         | 57.4±1.6                 | 58.3±1.3   | 0.66    |
| LA (mm)          | 45.0±2.2                 | 42.9±1.3   | 0.37    |
| LVEDd (mm)       | 53.1±1.9                 | 54.4±1.6   | 0.62    |
| LVESd (mm)       | 34.4±1.8                 | 34.3±1.6   | 0.98    |
| IVSd (mm)        | 9.6±0.4                  | 10.6±0.4   | 0.08    |
| LVPWd (mm)       | 9.4±0.3                  | 10.0±0.3   | 0.21    |
| PAP (mmHg)       | 39.1±3.5                 | 37.8±2.3   | 0.76    |
| Medication, n    |                          |            |         |
| Diuretics        | 5                        | 7          | 0.4     |
| β-Blockers       | 4                        | 5          | 0.37    |
| Digitalis        | 1                        | 6          | 0.29    |
| ACEI or AT antagonist | 8                      | 9          | 0.1     |
| Calcium antagonist| 3                        | 5          | 0.7     |
| Aldosterone antagonist | 3                    | 4          | 0.49    |
| Statin           | 2                        | 2          | 0.41    |
| Nitrate          | 4                        | 3          | 0.12    |

Values are means ± SEM.

https://doi.org/10.1371/journal.pone.0173759.t002
Real-time PCR

Real-time PCR tests have shown that the mRNA expressions of TGFβ1, TRAF6 and CTGF in the postoperative AF group were significantly higher than those in the sinus rhythm group (Fig 2A, 2B and 2C).

Serum Ang II levels

Serum Ang II levels were significantly higher in patients who developed AF versus those who remained in SR (Fig 2D).

Western blotting

Western blotting demonstrated that P38 MAPKs, ERK1/2 and the degree of JNK phosphorylation were higher in the postoperative AF group than in the sinus rhythm group (p<0.05; Fig 3). The protein expressions of TGFβ1, TRAF6 and CTGF and TAK1 phosphorylation in the postoperative AF group were significantly higher than those in the sinus rhythm group (p<0.05; Fig 4). Taken together, these results confirmed that the MAPKs/TGF-β1/TRAF6 signaling pathway is involved in the development of atrial fibrosis in patients with rheumatic heart disease.

Discussion

In this study we showed that patients without a history of AF who develop postoperative AF have a higher percentage of LA fibrosis, increased expression of TRAF6, higher serum Ang II levels, and changes in the activities of the MAPKs/TGF-β1/TRAF6 pathway. Because our team have previously demonstrated that the MAPKs/TGF-β1/TRAF6 signaling pathway is important in atrial fibrosis development in cultured mice fibroblasts [7], we propose that MAPKs/TGF-β1/TRAF6 is also an important signaling pathway in AngII-induced CTGF expression, which also plays an important role in human atrial structural remodeling (Fig 5).
Fig 2. The mRNA expression of TGF\(\beta\)1 (A), TRAF6 (B) and CTGF (C) in the postoperative AF group was markedly higher than that in the SR group. In each group, tissue samples from 15 random patients were used. All experiments were performed 3 times. Serum Ang II levels were measured in all patients and were significantly higher in patients who developed AF versus those who remained in SR (D). Bars correspond to the mean ± SEM. SR = remained in normal sinus rhythm, AF = developed new onset postoperative atrial fibrillation, **p<0.01, *p<0.05.

https://doi.org/10.1371/journal.pone.0173759.g002
Fig 3. A: Representative western blot of MAPKs. Each band represents one patient with either postoperative AF or SR. The protein expression of phosphorylated P38 MAPKs (B), ERK1/2 (C) and JNK (D) in the postoperative AF group was significantly higher than that in the SR group. Bars correspond to the mean ± SEM. In each group, tissue samples from 15 random patients were used. All experiments were performed 3 times. SR = remained in normal sinus rhythm, AF = developed new onset postoperative atrial fibrillation, *p<0.05.

https://doi.org/10.1371/journal.pone.0173759.g003
The exact mechanism and signal transduction pathway underlying atrial muscle fibrosis is unknown [6]. Studies in recent years have noted that the following mechanisms are mainly involved in atrial fibrosis: 1) the renin angiotensin aldosterone system (RAAS), 2) TGF-β and 3) inflammation and oxidative stress. Of these, the study of the RAAS system activation mechanism resulting in atrial structural remodeling was relatively thorough.

Ang II is a key link between the RAAS system and atrial fibrosis. In animal models of overexpression of angiotensin converting enzyme (ACE), significantly increased AngII levels
resulted in distinct atrial enlargement and atrial fibrosis and eventually caused the occurrence of AF [8] and up-regulation of angiotensin type I receptor (AT1R) expression was found in atrial tissues of patients with AF. [9]. Further studies have found that RAAS inhibitors can inhibit atrial fibrosis and atrial structural remodeling and slow down the occurrence of AF [10,11]. Our finding of increased levels of Ang II in patients who develop postoperative AF also supports this hypothesis.

Studies have discovered that the activation of MAPKs played an important role in atrial structural remodeling. MAPKs, a crucial downstream signaling molecule of AngII, participated in the process of up-regulation of TGF-β1 expression induced by AngII [12–14] which has been considered to be the main mechanism underlying atrial fibrosis. Our previous study found that AngII can improve MAPKs activation, up-regulate expression of TGF-β1 and CTGF, and enhance cell proliferation [7]. This study determined that compared with the patients in sinus rhythm, the degree of MAPKs activation in atrial tissue was significantly increased in patients who developed postoperative AF.

Fig 5. AngII-induced MAPK/TGF-β1/TRAF6/TAK1 signaling pathway in postoperative atrial fibrillation.

Binding of Ang II to AT1 receptor induces activation of MAPK, which increases the expression of TGF-β1. Then, paracrine production of TGF-β1 activates the signaling pathway of TRAF6/TAK1. Activation of the above signaling pathway promotes the proliferation of atrial fibroblasts, leading to atrial fibrosis.
TGF-β1, a key growth factor in fibrosis, can regulate cell proliferation, apoptosis and migration, and extracellular matrix synthesis. It up-regulates the expression of fibronectin and collagen, [15] and the over-expression of TGF-β1 can lead to the occurrence of atrial fibrosis and AF through up-regulation of CTGF expression [16] [12,17]. This study has shown that compared with the patients with sinus rhythm, the mRNA and protein expression of TGF-β1 and CTGF in atrial tissue were significantly elevated in the patients without a history of AF who developed postoperative AF.

Studies have shown that TGF-β1 promoted the occurrence of atrial fibrosis through both downstream Smad signaling [18] and Smad-independent pathways. The TRAF6/TAK1 signaling pathway plays a key role in the activation of TGF-β1/non-Smad signaling pathways. The tumor necrosis factor receptor is an important intra-cytoplasmic adaptor molecule; these types of molecules have a TRAF structure domain of approximately 230 amino acids and a characteristic C terminus [19]. At present, TRAF6 is one of 6 types of TRAF molecules identified in mammals; it achieves its biological effect mainly through signal transduction pathways. After TGF-β1 activated the TGF-receptor, it promoted TRAF6 ubiquitination, thereby prompting the combination of TRAF6 with TAK1, and then ubiquitination of TAK1 at lysine 63 and 158, thereby further activating the downstream signaling pathway [20,21]. Studies have reported that the activation of the TRAF6/TAK1 signaling pathway induced by TGF-β1 is involved in apoptosis, inflammation and epithelial mesenchymal transformation [22]. This study determined that the protein expressions of TRAF6 and CTGF and TAK1 phosphorylation in the atrial tissue of patients who develop AF after cardiac surgery with no previous history of AF were significantly higher than those in the sinus rhythm group. Because we previously found that AngII stimulated mouse atrial fibroblasts and that TGF-β1 played a role through the Smad-independent pathway [7], we verified that the TGF-β1/TRAF6 signaling pathway was involved in the development of atrial fibrosis.

However, this study has some limitations. Although all patients had no known history of AF, some could have had prior episodes of asymptomatic AF as pre-operative Holter monitoring was not performed. In addition, we only compared the expression of the related molecules in atrial tissue, but no further extraction and culture of atrial fibroblasts was performed to observe the effect of AngII and TRAF6 on fibroblast proliferation in human atrial tissue and on the MAPKs/TGF-β1/TRAF6 signaling pathway. Therefore, our study verified only that this signaling pathway is altered in the development of atrial fibrosis in patients with no history of AF who developed AF after cardiac surgery.

In summary, our study determined that the occurrence of postoperative AF in patients who have no previous history of AF was correlated with atrial fibrosis and that the MAPKs/TGF-β1/TRAF6 signaling pathway was altered in these patients, which suggests that this pathway is an important signaling pathway in the CTGF expression induced by AngII.

**Supporting information**

S1 Dataset. Patient variables, fibrosis scores and Ang II levels.
(XLSX)

S2 Dataset. Results of quantitative real-time PCR.
(XLSX)

S3 Dataset. Results of western blot assay.
(XLSX)
Author Contributions

Conceptualization: XL.

Data curation: QW.

Formal analysis: DZ.

Funding acquisition: XL.

Investigation: YZ XC.

Methodology: DZ.

Project administration: DZ.

Resources: DZ SW.

Software: DZ.

Supervision: XL.

Validation: DZ.

Visualization: DZ.

Writing – original draft: DZ.

Writing – review & editing: DZ.

References

1. Tan AY, Zimetbaum P (2011) Atrial fibrillation and atrial fibrosis. J Cardiovasc Pharmacol 57: 625–629. https://doi.org/10.1097/FJC.0b013e3182073c78 PMID: 21633248

2. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J (2002) Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 54: 361–379. PMID: 12062341

3. Beyerbach DM, Zipes DP (2004) Mortality as an endpoint in atrial fibrillation. Heart Rhythm 1: B8–18, discussion B18-19. https://doi.org/10.1016/j.hrthm.2004.04.018 PMID: 15851134

4. Swartz MF, Fink GW, Sarwar MF, Hicks GL, Yu Y, Hu R, et al. (2012) Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation. J Am Coll Cardiol 60: 1799–1806. https://doi.org/10.1016/j.jacc.2012.06.048 PMID: 23040566

5. LaPar DJ, Speir AM, Crosby IK, Fonner E Jr., Brown M, Rich JB, et al. (2014) Postoperative atrial fibrillation significantly increases mortality, hospital readmission, and hospital costs. Ann Thorac Surg 98: 527–533; discussion 533. https://doi.org/10.1016/j.athoracsur.2014.03.039 PMID: 25087786

6. Burstein B, Nattel S (2008) Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 51: 802–809. https://doi.org/10.1016/j.jacc.2007.09.064 PMID: 18294563

7. Gu J, Liu X, Wang QX, Tan HW, Guo M, Jiang WF, et al. (2012) Angiotensin II increases CTGF expression via MAPKs/TGF-beta1/TRAF6 pathway in atrial fibroblasts. Exp Cell Res 318: 2105–2115. https://doi.org/10.1016/j.yexcr.2012.06.015 PMID: 22749815

8. Xiao HD, Fuchs S, Campbell DJ, Lewis W, Dudley SC Jr., Kasi VS, et al. (2004) Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 165: 1019–1032. https://doi.org/10.1016/S0002-9440(10)63363-9 PMID: 15331425

9. Boldt A, Wetzal U, Weigel J, Garbade J, Lauschke J, Hindricks G, et al. (2003) Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 42: 1785–1792. PMID: 14642889

10. Nakashima H, Kumagai K (2007) Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. Circ J 71: 1977–1982. PMID: 18037757

11. Huang G, Xu JB, Liu JX, He Y, Nie XL, Li Q, et al. (2011) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis. Eur J Clin Invest 41: 719–733. https://doi.org/10.1111/j.1365-2362.2010.02460.x PMID: 21250083
12. Liu B, Yu J, Taylor L, Zhou X, Polgar P (2006) Microarray and phosphokinase screenings leading to studies on ERK and JNK regulation of connective tissue growth factor expression by angiotensin II 1a and bradykinin B2 receptors in Rat1 fibroblasts. J Cell Biochem 97: 1104–1120. https://doi.org/10.1002/jcb.20709 PMID: 16294326

13. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883–891. https://doi.org/10.1056/NEJMoa1009638 PMID: 21830957

14. Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N (2004) Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am J Physiol Renal Physiol 286: F278–287. https://doi.org/10.1152/ajprenal.00139.2003 PMID: 14583433

15. Khan R, Sheppard R (2006) Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118: 10–24. https://doi.org/10.1111/j.1365-2567.2006.02336.x PMID: 16630019

16. Verheule S, Sato T, Everett Tt, Engle SK, Otten D, Rubart-von der Lohe M, et al. (2004) Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 94: 1458–1465. https://doi.org/10.1161/01.RES.0000129579.59664.9d PMID: 15117823

17. Ko WC, Hong CY, Hou SM, Lin CH, Ong ET, Lee CF, et al. (2011) Elevated expression of connective tissue growth factor in human atrial fibrillation and angiotensin II-treated cardiomyocytes. Circ J 75: 1592–1600. PMID: 21576930

18. He X, Gao X, Peng L, Wang S, Zhu Y, Ma H, et al. (2011) Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. Circ Res 108: 164–175. https://doi.org/10.1161/CIRCRESAHA.110.234369 PMID: 21127293

19. Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S, et al. (2000) Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res 254: 14–24. https://doi.org/10.1006/excr.1999.4733 PMID: 10623461

20. Yamashita M, Fatyol K, Jin C, Wang X, Liu Z, Zhang YE (2008) TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell 31: 918–924. https://doi.org/10.1016/j.molcel.2008.09.002 PMID: 18922473

21. Yafei N, Belin J, Smith T, Crompton M (1990) Cyclosporin and mitochondrial phospholipid degradation. Biochem Soc Trans 18: 864–865. PMID: 2083713

22. Landstrom M (2010) The TAK1-TRAF6 signalling pathway. Int J Biochem Cell Biol 42: 585–589. https://doi.org/10.1016/j.biocel.2009.12.023 PMID: 20060931